vs
Anteris Technologies Global Corp.（AVR）与Bone Biologics Corp（BBLG）财务数据对比。点击上方公司名可切换其他公司
Anteris Technologies Global Corp.的季度营收约是Bone Biologics Corp的1215.7倍（$310.0K vs $255）。Anteris Technologies Global Corp.净利率更高（-9420.0% vs -339596.1%，领先330176.1%）
Anteris Technologies Global Corp是一家专注于结构性心脏病诊疗解决方案的医疗科技企业，开发及商业化生物假体心脏瓣膜、经导管介入产品，服务北美、欧洲及亚太地区的医疗机构，核心业务覆盖心脏外科与介入心脏病学领域。
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
AVR vs BBLG — 直观对比
营收规模更大
AVR
是对方的1215.7倍
$255
净利率更高
AVR
高出330176.1%
-339596.1%
损益表 — Q4 2025 vs Q1 2024
| 指标 | | |
|---|---|---|
| 营收 | $310.0K | $255 |
| 净利润 | $-29.2M | $-866.0K |
| 毛利率 | 70.6% | — |
| 营业利润率 | -9343.5% | -354327.8% |
| 净利率 | -9420.0% | -339596.1% |
| 营收同比 | — | -54.1% |
| 净利润同比 | — | 76.7% |
| 每股收益（稀释后） | $-0.74 | $-1.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVRBBLG
| Q4 25 | $310.0K | — | ||
| Q3 25 | $429.0K | — | ||
| Q2 25 | $618.0K | — | ||
| Q1 25 | $556.0K | — | ||
| Q1 24 | — | $255 | ||
| Q4 23 | — | $348 | ||
| Q3 23 | — | $536 | ||
| Q2 23 | — | $428 |
净利润AVRBBLG
| Q4 25 | $-29.2M | — | ||
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.8M | — | ||
| Q1 25 | $-21.9M | — | ||
| Q1 24 | — | $-866.0K | ||
| Q4 23 | — | $-1.5M | ||
| Q3 23 | — | $-1.9M | ||
| Q2 23 | — | $-1.8M |
毛利率AVRBBLG
| Q4 25 | 70.6% | — | ||
| Q3 25 | 71.3% | — | ||
| Q2 25 | 76.1% | — | ||
| Q1 25 | 62.8% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
营业利润率AVRBBLG
| Q4 25 | -9343.5% | — | ||
| Q3 25 | -5190.0% | — | ||
| Q2 25 | -3379.3% | — | ||
| Q1 25 | -3917.3% | — | ||
| Q1 24 | — | -354327.8% | ||
| Q4 23 | — | -333335.6% | ||
| Q3 23 | — | -388225.7% | ||
| Q2 23 | — | -710249.5% |
净利率AVRBBLG
| Q4 25 | -9420.0% | — | ||
| Q3 25 | -5185.1% | — | ||
| Q2 25 | -3371.2% | — | ||
| Q1 25 | -3932.4% | — | ||
| Q1 24 | — | -339596.1% | ||
| Q4 23 | — | -445369.3% | ||
| Q3 23 | — | -358154.7% | ||
| Q2 23 | — | -413373.4% |
每股收益（稀释后）AVRBBLG
| Q4 25 | $-0.74 | — | ||
| Q3 25 | $-0.62 | — | ||
| Q2 25 | $-0.58 | — | ||
| Q1 25 | $-0.61 | — | ||
| Q1 24 | — | $-1.31 | ||
| Q4 23 | — | $31.30 | ||
| Q3 23 | — | $-4.90 | ||
| Q2 23 | — | $-5.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $22.0K | — |
| 股东权益账面价值 | $-93.0K | $3.7M |
| 总资产 | $23.0M | $3.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AVRBBLG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $49.0M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
总债务AVRBBLG
| Q4 25 | $22.0K | — | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $30.0K | — | ||
| Q1 25 | $30.0K | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
股东权益AVRBBLG
| Q4 25 | $-93.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $24.4M | — | ||
| Q1 25 | $43.3M | — | ||
| Q1 24 | — | $3.7M | ||
| Q4 23 | — | $2.9M | ||
| Q3 23 | — | $3.8M | ||
| Q2 23 | — | $5.7M |
总资产AVRBBLG
| Q4 25 | $23.0M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $39.9M | — | ||
| Q1 25 | $58.8M | — | ||
| Q1 24 | — | $3.8M | ||
| Q4 23 | — | $3.7M | ||
| Q3 23 | — | $5.0M | ||
| Q2 23 | — | $7.6M |
负债/权益比AVRBBLG
| Q4 25 | — | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.5M | $-1.3M |
| 自由现金流经营现金流 - 资本支出 | $-18.9M | — |
| 自由现金流率自由现金流/营收 | -6104.5% | — |
| 资本支出强度资本支出/营收 | 128.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-79.8M | — |
8季度趋势，按日历期对齐
经营现金流AVRBBLG
| Q4 25 | $-18.5M | — | ||
| Q3 25 | $-18.3M | — | ||
| Q2 25 | $-19.5M | — | ||
| Q1 25 | $-21.5M | — | ||
| Q1 24 | — | $-1.3M | ||
| Q4 23 | — | $-2.0M | ||
| Q3 23 | — | $-2.6M | ||
| Q2 23 | — | $-3.6M |
自由现金流AVRBBLG
| Q4 25 | $-18.9M | — | ||
| Q3 25 | $-19.0M | — | ||
| Q2 25 | $-20.1M | — | ||
| Q1 25 | $-21.7M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
自由现金流率AVRBBLG
| Q4 25 | -6104.5% | — | ||
| Q3 25 | -4434.5% | — | ||
| Q2 25 | -3247.9% | — | ||
| Q1 25 | -3909.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
资本支出强度AVRBBLG
| Q4 25 | 128.1% | — | ||
| Q3 25 | 180.0% | — | ||
| Q2 25 | 86.9% | — | ||
| Q1 25 | 44.6% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
